tings where exposure was uneected. When the etiology of a case of granulomatous pulmonary disease is not determined, sarcoidosis is the "diagnosis of exclusion." This The number of CBD cases that could meet the definition, but were not identified and added to the registry is unknown. There is evidence that sarcoidosis is diagnosed without adequately excluding CBD (6) . Also, researchers using modern laboratory methods have shown that some patients who do not meet the registry criteria do have CBD (11 Immunology of CBD. The early health studies of beryllium were difficult to interpret because the dose that produced disease appeared to vary considerably, disease severity did not correlate with tissue levels, and the latency period was often long (13, 14) . These characteristics lead (as early as 1951) to the postulation of an immune mechanism (15); however, because beryllium has a very low molecular weight, this ability to induce an immune response was unexpected. Much of the research on CBD has focused on understanding this immune response and developing a reliable test for beryllium hypersensitivity (16) .
In 1951, cutaneous hypersensitivity to beryllium was described and a patch test developed; a positive test at 72 hr was considered evidence of beryllium hypersensitivity and of CBD in patients with granulomatous lung disease (17, 18) . However, cutaneous hypersensitivity developed in 8 of 16 previously unexposed controls, and at least one fatality was associated with the patch test (19 (26) recently studied the genes that encode the 1-chain in 33 cases (exposed workers with CBD) and 44 controls (exposed workers without CBD). These researchers found that 97% (32/33) of the cases exhibited the amino acid glutamate (rather than lysine) at position 69 of a cell-surface glycoprotein involved in antigen recognition. This marker (Glu69) was present in only 30% (13/ 
Summary
CBD has historically been a difficult diagnosis to make with certainty; the diagnosis has typically required physicians to document beryllium exposure by history or by demonstrating excess beryllium in biologic specimens, and to meet certain clinical and pathologic criteria for chronic granulomatous pulmonary disease, criteria that are also present in other granulomatous diseases such as sarcoidosis.
In routine medical practice, the lack of a known (typically occupational) exposure has usually precluded active consideration of CBD in patients with granulomatous disease. If no other etiology is found, sarcoidosis has been the diagnosis of exclusion. This approach has rested upon unstated assumptions that 1) the only significant exposures are occupational; 2) the worker and employer know about the exposure; 3) the exposure is disclosed to the physician; and 4) the physician understands the clinical implications of beryllium exposure.
The validity of these assumptions has not been tested, and in some recent cases it is demonstrably false. When the clinical findings are consistent with granulomatous disease, CBD can now be diagnosed (or excluded) by assessing the immune response to beryllium (28) . This specialized testing requires a priori coordination with an appropriate laboratory.
The best time to consider CBD is during the initial evaluation of patients with granulomatous pulmonary disease because a diagnostic bronchoscopy is usually performed. An LPT using BAL lymphocytes is the gold standard for diagnosing or excluding CBD; while a positive LPT using peripheral blood lymphocytes can also support the diagnosis, a negative test does not exclude it.
Recommendations
The state of the art for beryllium-related biomedical testing has advanced significantly, and reliable testing is available in a few centers. The following proposed guidelines are intended to encourage physicians to consider testing in the presence of uncertainty about the potential for beryllium exposure: Uncertainties about beryllium exposure can also be affected by a physician's knowledge of industry; two physicians might appropriately make different decisions about testing in similar situations. The following points are offered to support the consideration of testing when the patient's potential for exposure is uncertain: 1) chronic granulomatous disease is potentially a life-threatening condition; 2) management decisions and prognosis are clarified by recognizing CBD; 3) the diagnostic test (LPT) is very specific for beryllium hypersensitivity when performed by an experienced laboratory; 4) exposure and disease can be widely separated in time and location; 5) exposure histories are not always reliable; and 6) a case of CBD can have public health significance as a sentinel case.
